BOSTON, Mass. and AUSTIN, Texas, July 07, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated central nervous system (CNS) precision neuroscience biopharmaceutical company, and Remagine Labs, Inc., a developer of electronically controlled transdermal drug delivery systems, today announced a research collaboration and license agreement to develop an iontophoretic transdermal patch for the […]
The FDA recently cleared Cala kIQ Plus, an updated, wrist-worn transcutaneous afferent patterned stimulation (TAPS) system, for the temporary relief of action hand tremor in essential tremor (ET) and postural and kinetic tremor symptoms in Parkinson disease (PD). Developed by Cala Health, the device was authorized through the 510(k) pathway on the basis of substantial equivalence […]
SAN MATEO, Calif., May 8, 2026 /PRNewswire/ — Cala®, the bioelectronic medicine leader, announced today the Cala kIQ® System has been named “Best New Neurology Technology Solution” as part of the 2026 MedTech Breakthrough Awards. The awards honor excellence and recognize innovation, hard work, and success in various health and medical technology categories.
There’s some renewed hope for the most common movement disorder, even more prevalent than Parkinson’s disease. Essential tremor impacts 7 million Americans who navigate their condition without a targeted treatment. Finally, that’s about to change. Unlike Parkinson’s disease, which is tremor at rest, essential tremor presents during action, says Dr. Jill Farmer.
SAN MATEO, Calif. and CHICAGO, April 15, 2026 /PRNewswire/ — Cala®, the bioelectronic medicine leader, today announced U.S. Food and Drug Administration (FDA) clearance of the Cala kIQ® Plus system, the next-generation of its wearable neurostimulation device for action hand tremor in essential tremor (ET) and Parkinson’s disease (PD). Cala kIQ Plus is the latest advancement in TAPS® technology – […]
BOSTON, April 14, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for ulixacaltamide HCl for the treatment of essential tremor (ET) in adults. The FDA has set […]
HAIFA, Israel and FRANKFURT, Germany, March 3, 2026 /PRNewswire/ — Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced that France has officially published national reimbursement for unilateral MR–guided focused ultrasound treatment for medication–refractory essential tremor. The new Diagnosis Related Groups and tariffs were released in the Journal Officiel de la République […]
BOSTON–(BUSINESS WIRE)–Encora Therapeutics, a leader in non-invasive neuromodulation technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Encora X1™. This clearance is supported by data from two clinical studies: a randomized, sham-controlled trial and a 90-day home-use study. Together, these studies demonstrated consistent improvements in tremor severity […]
SAN MATEO, Calif., Feb. 9, 2026 /PRNewswire/ — Cala®, the bioelectronic medicine leader, today announced publication of a retrospective analysis of the multicenter PROSPECT trial of TAPS® therapy, in the peer-reviewed journal, Tremor and Other Hyperkinetic Movements. The study assessed underlying tremor improvement in essential tremor (ET) patients, evaluated after months of consistent use of TAPS therapy, which is differentiated […]
HAIFA, Israel and MIAMI, Feb. 5, 2026 /PRNewswire/ — Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced it has received a Medical Device License from Health Canada for its Exablate® Prime system. Previously approved by the U.S. Food and Drug Administration (FDA), this approval expands access to incisionless, MR-guided focused […]